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Cost analysis of type 2 diabetes mellitus treatment in economically 
developed countries 
 
Abstract  
Introduction: There is a growing need to evaluate the factors contributing to the increase in 
health expenditures, as well as the cost of medicines used in the treatment of T2DM in the 
economically developed countries.   
 Areas covered: A systematic searching of studies describing the direct cost of T2DM and 
medicine cost of treating T2DM. The quality of the studies found eligible for this study were 
assessed using a methodological quality appraisal tool. Nine studies were included in this 
review. All the included studies had data on direct cost and antidiabetic medicine cost of health 
care.  Mean annual direct cost per person/year ranged between US$220 and US$7,600. The 
two components with the greatest impact on direct cost was found to be medicines and 
hospitalization. The mean annual medicines cost per person/year was found to range between 
US$140 and US$2,990. 
Expert commentary: There is an increased expenditure on treatment of T2DM. However, it 
is still not clear how the increased use of antidiabetic medicines is reflected in the overall 
expenditures. Further, we suggest a more comprehensive understanding of prescription patterns 
as older drug are more expensive than the newer drugs hence they are still under patent. 
 
1. Introduction  
Type 2 diabetes mellitus (T2DM) is a metabolic disorder caused by increased blood glucose 
levels.  Previously this disease was known as non-insulin-dependent diabetes and was most 
often diagnosed in people over 40 years. However, T2DM has now become a more common 
disease and an increasing number of children and younger adolescents present with diabetes 
(Diabetes.co.uk; Hsia et al., 2009).  According to the international diabetes federation, one in 
eleven adults has diabetes. This equals 424.9 million people at a global level.  Further, 210 
million adults with diabetes are estimated to be unaware of their disease (IDF, 2018).  T2DM 
is considered a global health problem and prevalence has been found to be rising in recent years 
and expected to keep growing.  This phenomenon has been found to evolve in association with 
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cultural changes, an aging population, increased consumption of unhealthy foods and reduced 
physical activity (IDF, 2018; Saito et al., 2011).   
Global health expenditure in 2006 for people aged 20-79 was found to be $232 in 2017 it had 
increased to $727, and this number is expected to further increase to $776 by 2045. The 
projection for 2045 may be underestimated as it includes the mean expenditure per person and 
diabetes prevalence rate to remain constant (IDF, 2018). Despite the fact that most people with 
diabetes live in low- and middle-income countries, studies show that 80 % of all global health 
expenditure is projected to be in the world’s economically richest countries (Zhang et al., 
2009). Hence, there is a need to create awareness about generic prescribing, reimbursement of 
medicines and implementation of international guidelines into current practices (Babar et al., 
2011; IDF, 2018; Zhang et al., 2009). 
 
In this current context, the aim of this review is to synthesise studies which are evaluating the 
cost of medicines used in the treatment of T2DM in the economically developed countries.   
  
2. Scope of the review 
We performed the cost analysis of medicines used in the treatment of T2DM in developed 
countries. PubMed, EMBASE, CINAHL, Cochrane Database of Systematic Reviews (CDSR) 
and Springer Link were reviewed for original articles. The reviewed papers considered T2DM 
from a health services or society perspective.  The electronic search strategy included keywords 
such as, pharmaceuticals (e.g.  “cost”, “costs”, “expenditure”), medicines (e.g.  “drug” “drugs”, 
“glucose lowering drugs”, “medications”, “medicine” or “medicines”), diabetes (e.g.  “Type 2 
diabetes”, “Type 2 diabetes mellitus” or “hypoglycaemia”) and economics (e.g. “direct cost”, 
“hospitalization”, “service cost”, “cost of illness“ or “health care cost”).  The same keywords 
and search combinations were used in all databases. Included articles were published between 
2007 to 2017. The included articles were written in the English language and required full-text 
to be available.  
The review was limited to studies that evaluate the direct cost of T2DM and cost of medicines. 
Studies evaluating on policy changes of cost of medicines were left out. Further, we excluded 
studies that (i) did not distinguish between type 1 diabetes mellitus (T1DM) and T2DM, (ii) 
reported on cost of complication and comorbidities related to T2DM, (iii) did not assess 
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relevant outcomes, and (iv) did not report on original data. The exclusion criteria are available 
in Table 1.  
 
Relevant data regarding study population and study characteristics were extracted from the 
original data chosen. The standardised protocol and reporting form was adopted from PRISMA 
guidelines (Liberati et al., 2009) (appendix 1). Information on study design (e.g. cohort, cross-
sectional, bottom up approach), sample size (number of patients diagnosed with T2DM), data 
source (e.g. medical charts, interviews and questionnaires) and inclusion criteria (e.g. diagnosis 
codes used) are presented in table 2.  
 
Table 1 Exclusion criteria 
Exclusion criteria 
 Studies that does not quote costs in results section 
 Studies on adherence  
 Studies on the saving on using one drug class instead of other  
 Studies on comorbidities e.g. chronic kidney disease, heart conditions, obesity/lifestyle 
interventions 
 Studies that do not differentiate between T1 and T2DM 
 Studies that consider diabetic complications e.g. diabetes foot, diabetic nephropathy  
 Cost-effectiveness, cost-utility and cost minimisation studies  
 Studies on developing countries  
 Conference abstracts, reviews, book etc. 
 Diabetes with other co-morbidities (e.g. heart condition) 
 Pharmacodynamics and pharmacokinetic studies  
 Animal and in vitro studies  
 
Table 2  Characteristics of included studies 
Country Setting for study 
recruitment 
Study design  Methods Study 
duration 
(year) 
Sample 
size 
(n) 
 
Funding body Inclusion criteria Mean 
age 
(years) 
Males 
(%) 
Brazil 
(Bahia et al., 2011) 
Primary, secondary and 
tertiary care units  
Retrospective study Questionnaire/ interviews 
and Medical records 
 
2007 1000 Publicly 
financed 
 
Diagnosed T2DM, no further 
specification 
 
59 33.5 
Brazil 
(Borges, Ferraz, & 
Chacra, 2014) 
Diabetes care centre, 
tertiary care  
Retrospective study Interviews and reviews of 
medical charts, and 
questionnaires 
 
2009-
2010 
209 Publicly 
financed 
 
T2DM patients over 18 and having 
regular follow-up consultations 
63 42 
Nothern Italy 
(Demurtas et al., 2017) 
Tertiary sector Retrospective study Medical records 
 
2012 24.087 Publicly 
financed 
 
Diabetes classified as “insulin 
treated diabetes”, and “non-insulin 
treated diabetes” above 45 years 
 
69.2 52 
Lithuana 
(Domeikiene, Vaivadaite, 
Ivanauskiene, & Padaiga, 
2014) 
Secondary care, 
ambulatory and 
hospital inpatient care 
Top down approach  Medical records 
 
2011 762 Publicly 
financed 
 
T2DM, ICD-10 diagnosis codes 
E11.0-9 
67.07 37.7 
Agentina 
(Elgart et al., 2014) 
Secondary care, 
hospital care  
Observational 
retrospective study 
telephone interviews and 
medical records 
 
2011 387 Publicly and 
privately 
financed 
T2DM, ICD-10 63 45 
Germany 
(Jacob, von Vultee, & 
Kostev, 2017) 
General practices and 
diabetic centres  
Retrospective study Medical records 2015 36382 Publicly and 
privately 
financed  
Diagnosed T2DM 
 
N/A 52.2 
Spain 
(Mata-Cases et al., 2016) 
Primary care Retrospective study Medical records 2011 126811 Publicly 
financed 
T2DM, ICD-10 diagnosis codes E11, 
E14 
67.5 53.5 
Singapore 
(Shuyu Ng, Toh, Ko, & 
Yu-Chia Lee, 2015) 
Hospital and clinic  Buttom up approach/ 
cross-sectional study  
 2010 500 Publicly 
financed 
 
T2DM, ICD-9 code of 250 69 44.6 
Germany 
(Ulrich et al., 2016) 
Generel practitioner  Retrospective study Questionnaires 2004-
2012 
6803 Publicly and 
privately 
financed 
Diagnosed T2DM, no further 
specification 
 
71 54.1 
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The findings were categorized into: i) mean annual direct cost, (ii) mean annual antidiabetic 
medicine cost, (iii) components included in the estimation for direct cost, and (iv) antidiabetic 
medicines included medicine cost (where possible cost of medicines for other conditions than 
diabetes has been excluded).  When cost was expressed in other values than mean annual cost, 
these were calculated based on the published findings.  The currency used for costs was 
calculated to express the corresponding 2017 values for US dollars. A 2 percent inflation rate 
has been used for these calculation (Barua, 2017). The exchange rate adopted in this study was 
1 USD = 1.998 and 1 USD = 0.0537 AR$, which was the average exchange rate reported on 
December 31st 2017 (Yahoo, 2018).  Where cost for both private and public tariffs were 
available it was preferred to use (i) average costs (ii) public tariff.   
Quality of the studies was assessed by using a methodological quality appraisal tool. The tool 
is adapted from previous systematic reviews of quantitative studies (Louw, Morris, & 
Grimmer-Somers, 2007; Roman, 2013; Wong, Cheung, & Hart, 2008). A study score was 
calculated to rate the quality of studies.  A study was scored 0 (no/not reported) or 1 (yes) for 
each study domain. The studies were judged on quality assessment items (e.g. response rate 
and applied tool) and relevance to current review (e.g. outcome measurements and study 
questions).  The quality rating of each item was evaluated on a “poor”, “fair” and “good” basis. 
Studies that scored from 0%–33.9% were considered weak, 34%–66.9% were considered 
moderate, and 67%–100% were interpreted as strong (Table 3).  
The examples of cost calculations are provided below: 
Example 1: Calculation of future value when currency is reported in US dollars:  
C= (1 + r)n 
, where C = future value, r = inflation (2%), and n = number of years since 2017 
Brazil future value: 1,335$ ∗ (1+0.02)12 = 1,718.47$ ~ 1720$ 
 
Example 2: Calculation of future value when reported currency is different from US dollars:  
C= (1 + r)n 
, where C = future value, r = inflation (2%), and n = number of years since 2017 
Northern Italy future value = 3,312€ ∗ (1 + 0.02)7 = 3,803.89€ ~ 3,800€ 
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Euros are now converted to US dollars. Exchange rate for last day of the year (31/12/2017) has 
been found to be 1.998.  
 Mean value expressed in 2017 dollars: 3803.89€ ∗ 1.998 = 7,600.18$   
  
 
4. Characteristics of the study populations  
Our search identified 625 unique studies of which thirty-four were found eligible for full-text 
screening (figure 1). Nine of these studies (Bahia et al., 2011; Borges, Ferraz, & Chacra, 2014; 
Demurtas et al., 2017; Domeikiene, Vaivadaite, Ivanauskiene, & Padaiga, 2014; Elgart et al., 
2014; Jacob, von Vultee, & Kostev, 2017; Mata-Cases et al., 2016; Shuyu Ng, Toh, Ko, & Yu-
Chia Lee, 2015; Ulrich et al., 2016) met our inclusion criteria. From the included original 
articles two studies are conducted in Brazil (Bahia et al., 2011; Borges et al., 2014) and 
Germany (Jacob et al., 2017; Ulrich et al., 2016) respectively, and one in Northern Italy 
(Demurtas et al., 2017), Lithuania (Domeikiene et al., 2014), Argentina (Elgart et al., 2014), 
Spain (Mata-Cases et al., 2016) and Singapore (Shuyu Ng et al., 2015). All nine studies, which 
Table 3  Quality appraisal tool  a, b  (Louw et al., 2007; Roman, 2013; Wong et al., 2008) 
Study Quality assessment items Relevance to current 
review 
 A B C D E F G H Score % 
(Bahia et al., 2011)  1 1 1 1 1 1 1 1 100 % 
(Borges, Ferraz, & Chacra, 2014) 1 1 1 1 1 1 1 1 100 % 
(Demurtas et al., 2017) 1 1 1 1 1 1 1 1 100 % 
(Domeikiene, Vaivadaite, 
Ivanauskiene, & Padaiga, 2014) 
1 1 1 1 1 1 1 1 100 % 
(Elgart et al., 2014) 1 1 1 1 1 1 1 1 100 % 
(Jacob, von Vultee, & Kostev, 2017) 1 1 1 1 1 0 1 1 87.5 % 
(Mata-Cases et al., 2016) 1 1 1 1 1 1 1 1 100 % 
(Shuyu Ng, Toh, Ko, & Yu-Chia Lee, 
2015) 
1 1 1 1 1 1 1 1 100 % 
(Ulrich et al., 2016) 1 1 1 1 1 1 1 1 100 % 
a Score: total score divided by the total number of items multiplied by 100 
b Quality appraisal score and match with the objectives of current review: Weak - 0-33.9%; Moderate - 
: 34-66.9%; Strong - 67-100% 
 
Abbreviations: 0 - No/not reported; 1 - Yes; A - Was the sample likely to be representative of the 
study population?; B - Was a response rate mentioned within the study?; C - Was the instrument 
used reliable?; D - Was the instrument used valid? E - Was it a primary data source? F – Does 
study evaluate on direct cost used to treat TD2M?; G – Does study evaluate on cost of medicines 
used to treat TD2M?; H – Does the patient have unambiguous diagnosis of T2DM? 
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were included in this article, have data on direct cost and antidiabetic medicine cost of health 
care.  
Participants for the selected studies are recruited from across the healthcare sector; primary 
care, secondary care, and tertiary care. All patients were identified to have T2DM and they met 
the requirement defined in the respective studies (table 1). The mean age for people in the 
studies ranged between 59 and 71. On average there were fewer number of males in the studies.  
The studies used different definitions of T2DM as inclusion criteria (table 2). Four studies 
(Bahia et al., 2011; Borges et al., 2014; Jacob et al., 2017; Ulrich et al., 2016) identified the 
patients to have T2DM without further specification. One study (Demurtas et al., 2017) 
differentiated between T1DM and T2DM by categorising their medication as “insulin treated 
diabetes” and “non- insulin treated diabetes”. Four studies (Domeikiene et al., 2014; Elgart et 
al., 2014; Mata-Cases et al., 2016; Ulrich et al., 2016) used ICD-9/ICD-10 codes to identify 
T2DM patients.  
The estimation of the direct cost has different components and these components varied among 
the studies. Included components are for example medications, diagnostic tests, hospitalization, 
laboratory tests (table 4). Similarly, the medicines considered in the calculation of cost of 
medicines varied in the reviewed studies (table 4). The included medication can be categorized 
as (i) diabetes and obesity, (ii) antidiabetics/ glucose lowering drugs, (iii) no explanation of 
which medicines were included.   
 
5. Medical cost associated with diabetes  
All the included studies were assessed to score “strong” on the quality appraisal tool (table 3). 
Table 4, summarizes the distribution of the direct cost of T2DM, and the cost of diabetes 
mellitus medicines in the included studies. Six studies (Bahia et al., 2011; Borges et al., 2014; 
Demurtas et al., 2017; Domeikiene et al., 2014; Jacob et al., 2017; Shuyu Ng et al., 2015)  
define medications as “antidiabetics”.  Three studies (Elgart et al., 2014; Mata-Cases et al., 
2016; Ulrich et al., 2016) defines medicines as “medicines used to treat T2DM”. Currencies 
and price year used in the included studies have all been converted to US dollars using 
exchange rates for December 31st 2017.  Currencies, price year and examples of calculation 
provided in the original studies can be found in appendix 2. 
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Table 1 Cost of mean annual direct cost per person and mean annual medicine cost per person in the included studies.  
Country Price 
year 
Currency/ 
exchange 
rate 
Income group 
classification 
Direct cost estimated on 
basis of following 
components 
Mean 
annual 
direct 
cost per 
person 
Mean annual 
direct cost per 
person 
expressed in 
US dollars 
2017 1,2 
Medication cost estimated on basis of  Mean annual  
antidiabetic 
medicine cost 
per person (% of 
total direct cost) 
Mean annual 
medicine cost 
per person 
expressed in 
US dollars 
2017 1,2 
Brazil 
(Bahia et al., 
2011) 
2005 1 USD = 
1.4 R$ 
Upper middle 
income 
Medications, 
diagnostic tests, 
procedures, medical 
supplies (such as 
blood glucose test strips), 
visits with health 
professionals (physicians, 
nurses, nutritionists, 
physical therapists, 
dentists, and 
psychologists), 
and hospital costs for 
emergency room visits 
(including 
provider fees only). 
1,360 1,720 Medications used were categorized into four 
groups: diabetes and obesity, cardiovascular 
and dyslipidemia, psychiatric, and others (all 
other classes of medications). 
250 (18.38%) 3202 
Brazil 
(Borges, Ferraz, 
& Chacra, 2014) 
2009 $ Upper middle 
income 
Procedures, 
hospitalizations, 
consultations, strips and 
tests/examinations and 
medications. 
1,000 1190 Medications was subdivided into four 
categories: antidiabetics, 
hypocholesterolinemics antihypertensives and 
others 
440 
(11.17%) 
490 
Nothern Italy 
(Demurtas et al., 
2017) 
2012 € High income Hospitalization, outpatient 
care cost, medications 
cost 
3.310 7,600 Medications included: (meglitinides,non-
sulfonylureas, sulfonylureas, thiazolidinediones, 
other antihyperglycemic agents, long and short-
acting insulins) 
870 (26.40 %) 10002 
Lithuana 
(Domeikiene, 
Vaivadaite, 
Ivanauskiene, & 
Padaiga, 2014) 
2011 1 EUR =  
3.45 LTL 
High income Type of treatment, 
diabetes-related chronic 
complications 
(microvascular and 
macrovascular), 
consultations of general 
practitioners and 
specialists, laboratory 
tests, covered drugs and 
diabetes 
supplies, ambulatory 
procedures, 
hospitalization, nursing 
9560 2,150 Direct cost of drugs are subdivided into: 
Antidiabetic medication , hypoglycemic 
medication, Oral and non-insulin injectable 
hypoglycemic medication, Oral hypoglycemic 
medication and insulin, Insulin  Diagnostics 
strips and Other medication 
450 (44.91 %) 500 
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services, healthcare at 
home costs 
Argentina 
(Elgart et al., 
2014) 
2011 AR$ High income Medications 
(including out-of-pocket 
payment for prescribed 
drugs), laboratory tests 
and procedures, 
hospitalizations, medical 
and other associated 
health professional 
outpatient 
visits (consultations). 
3,670 220 Does not differ between oral medicines used to 
treat T2DM w/o complications. 
2,6503 
(72.33 %) 
2990 
Germany 
(Jacob, von 
Vultee, & 
Kostev, 2017) 
2015 € High income N/A N/A N/A Nine different families of antihyperglycemic 
therapy were included in the analysis. The 
annual antihyperglycemic treatment cost per 
patient was calculated based on pharmacy retail 
prices. 
5004 520 
Spain 
(Mata-Cases et 
al., 2016) 
2011 € High income Primary care visits 
(differentiating between 
doctor’s or 
nurse’s visits, and 
between place of visit, i.e., 
in the office 
or at home), 
hospitalizations, referrals 
to specialist care, 
diagnostic tests, 
medication, dialysis 
treatment, and use of 
self-monitoring test strips. 
3110 7,140 Does not differ between medicines used to treat 
T2DM. The retail prices were based on the 
pharmacy billing information. 
930 (29.74 %) 
 
1060 
Singapore 
(Shuyu Ng, Toh, 
Ko, & Yu-Chia 
Lee, 2015) 
2010 1 USD = 
1.3 S$ 
High income Inpatient hospitalisation, 
accident and emergency 
(A&E) and ambulatory 
outpatient care (physician 
visits, allied 
health visits, laboratory 
tests and medications) 
1,580 1,800 The cost of drugs other than antidiabetics were 
not included. 
120 
(7.97 %) 
140 
Germany 
(Ulrich et al., 
2016) 
2011 € High income Outpatient services, 
hospital care, 
rehabilitation and 
medication 
3350 7,540 Does not differ between medicines used to treat 
T2DM. Pharmaceutical expenditures were 
calculated from information on name, 
pharmaceutical identification number and 
dosage of drug intake during the previous 7 
days. If pharmaceuticals were taken irregularly, 
the intake per week was assumed by using the 
defined daily dose (DDD). 
 
960 
(28.64 %) 
 
 
 
 
1080 
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1 Original values and calculations can be found in appendix 1 
2 Examples of calculations have been provided in methods section 
3 Expressed during a 3-month period (90 days) in original paper 
4 Estimate for overall population 
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Table 4 also shows the spending on mean annual direct costs person in Northern Italy ($7,600) 
(Demurtas et al., 2017), Spain ($7,140) (Mata-Cases et al., 2016) and Germany ($7,540) 
(Ulrich et al., 2016) are quite similar. The two studies conducted in Brazil report almost same 
direct cost respectively $1,720 (Borges et al., 2014) and $1,190 but varies in annual medicine 
cost which are reported to be $320 (Bahia et al., 2011) and $130 (Borges et al., 2014).  Almost 
two-fold difference is found in the cost of DM medicine in the two studies conducted in 
Germany,  $1040 (Jacob et al., 2017) and $2160 (Ulrich et al., 2016) respectively. The medicine 
cost varied from 8% to 72% of the mean annual direct cost per person. The lowest expenditures 
were reported in Singapore (Shuyu Ng et al., 2015) and highest expenditures were reported in 
Argentina (Elgart et al., 2014).  
Regardless of the methodology used in the individual study the mean annual direct cost was 
found to make a remarkable percentage of the mean annual cost. In Singapore $1,580 per 
person/year was estimated to be spent on direct cost. This is estimated to be higher than other 
Asian countries e.g. India (Tharkar, Devarajan, Kumpatla, & Viswanathan, 2010) and China 
(Wang et al., 2009).  The authors suggest this difference to be due to the fact that the findings 
in the two latter mentioned studies were reported without considering inflation.  
Expenses related to direct cost increases as disease progresses, age of the patient as well as the 
number of complications related to the condition (Bahia et al., 2011; Demurtas et al., 2017).  
The Italian NHS is especially challenged with this as there is expected to be an increased 
percentage of elderly compared to past, and thus the burden on the Italian NHS will be 
increased  (Demurtas et al., 2017).  This is in accordance with previous findings in the CODE-
2 study which reported that the prevention of diabetic complication may lead to a reduction in 
the overall healthcare expenditures (Williams, Van Gaal, & Lucioni, 2002).  There is a general 
agreement in the literature that policies that enforce prevention of diabetes and its complication 
are necessary as well as an optimization of healthcare resource allocation (Al-Maskari, El-
Sadig, & Nagelkerke, 2010; Bahia et al., 2011; Borges et al., 2014; Lee, 2011; Shuyu Ng et al., 
2015).   
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When looking at the cost components there are two trends; some countries have reported a low 
expenditure on medicines e.g. Northern Italy (20%) (Demurtas et al., 2017) , Spain (30%) 
(Mata-Cases et al., 2016), Singapore (8%) (Shuyu Ng et al., 2015) and Germany (29%) (Ulrich 
et al., 2016).  The CODE-2 study (Jonsson, 2002), which compares data from eight European 
countries, similarly reported a low expenditure on medicines (7 %) and a large direct cost on 
hospitalisation. Contrary the two studies conducted in Brazil shows a high expenditure on the 
medical component. In the first study conducted in Brazil (Bahia et al., 2011) the overall cost 
of medication was 48% versus 42% in (Borges et al., 2014).  This is similar to previous findings 
in Colombia (47%)(González, Walker, & Einarson, 2009), Iran (46%) (Javanbakht et al., 
2011).  We suggest that the difference in expenditure can be explained by two reasons. The 
first one is the number of generic prescriptions in these countries. A high rate of generic 
prescribing would lower the overall medicine cost. The second reason is the reimbursement 
cost of each medicine in the respective countries.  
 
6. Expert commentary 
Our review has shown an insight into the cost of antidiabetic medicines while treating T2DM 
across different countries. There are differences in cost components included in the 
estimation of direct cost, but the commonality is that all studies include the cost of medicines 
as a component. We find that the reported direct cost and cost of antidiabetic medicines can 
be compared keeping the methodological limitations T1DM in mind.  These assumptions are 
similar to previous studies which emphasizes on the importance of considering 
methodological approach when comparing the cost of diabetes (ADA, 2008, 2013; Bolin, 
Gip, Mörk, & Lindgren, 2009; Jonsson, 2002).  It was observed that the direct cost of T2DM 
was the significant component of overall health care cost.  As mentioned earlier, the 
economic burden of diabetes has increased with more than 50 % in the past 10 years. 
Although there is a consensus that the use of antidiabetic medicines has increased since the 
1990’s only one of the reviewed articles (Jacob et al., 2017) investigated prescription 
patterns.  This study reported that the annual expenditure on medicines was lower for 
metformin or sulfonylurea as compared to other glucose lowering agents such as Dipeptidyl 
peptidase-4 (DPP-4), Glucagon-like peptide-1(GLP-1), Sodium glucose transporter-2 (SGLT-
2). We suggest that the annual expenditure depends on the use generics i.e. metformin for 
sulfonylurea are older drugs, hence there is a lower cost compared to the newer drugs which 
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are still under patent. (Melander et al., 2006), conducted a study which investigated the cost 
of antidiabetic medicines in ten European countries and found large differences in the use of 
antidiabetic medicines between neighbouring countries. They explained this by differences in 
screening policies and management of T2DM e.g. true and detected prevalence of disease and 
therapeutic traditions.  
In the reviewed articles there is insufficient consideration to the factors that motivate the 
physicians prescribing behaviour e.g. price of the prescribed medicine, shared decision-making 
with patient and other external factors such as national and international guidelines. We find 
that pricing considerations when choosing which medicine to prescribe may be inappropriate 
as this would mean that all medicines are equally effective in all patients, which is not the case. 
Informed by national and international treatment guidelines, physicians should choose the most 
appropriate therapy for each individual patient.  Given that there is an increase in prevalence 
of diabetes and patients are being diagnosed at a younger age the challenges to health care are 
becoming more extensive. An understanding of the motivating factors for choosing medicines 
will help define the magnitude of the problem. It should also be mentioned that the reported 
estimates of medicine cost do not include the economic burden associated with lifestyle 
changes and bariatric surgery.  
The treatment of patients suffering from T2DM needs to be optimised in various settings.  
Firstly, there is a need to investigate on drug utilization and the economic burden of the 
prescribed medicines. Secondly, the increased efforts on glucose-lowering therapies has had 
an impact on diagnosis and health outcomes of patients suffering from T2DM.  Despite the 
increased efforts to get glycaemic control it is not clear the how use of antidiabetic medicines 
is being reflected in the overall expenditures.  We suggest a more comprehensive understanding 
of how physicians make choices about how they treat patients with T2DM, as well as a better 
understanding of the use of generic medicines, the influence of the patients and international 
guidelines in current practice. Lastly, a consensus approach to components included in 
estimates of economic evaluations would allow for more realistic and comparable cost 
estimates across countries.  
 
7. Five-year view  
In recent years, the financial burden of treating patients for T2DM has been projected to 
continue to increase and thus it is crucial to understand how each component contributes to 
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these costs.  Although several approaches have been taken to improve clinical outcomes i.e. by 
introducing target glycaemic levels and treatment guidelines many patients are still poorly 
managed.  It is crucial to understand the reason for hospitalisation among T2DM to reduce the 
need for emergency care. A focus on differences in cost between poorly controlled patients and 
controlled patients are required to fulfil this gap.  Despite the guidelines on treatment for T2DM 
none of the reviewed studies report on how the health care system in their country impact the 
way the physicians prescribe medicines. We find that the high expenditure on medicines can 
be kept down by increasing the use of generic medicines when treating patients with T2DM. 
The newer medicines are still under patents and thus cost more to prescribe than older 
medicines.  We wonder if the physicians’ prescribing behaviour is motivated by the national 
prescribing guidelines or are if they are steered by how much the insurance companies are 
willing to pay? It is important to mention that as prevalence increases the cost of treating 
complications related to T2DM will grow if current treatment regimens are maintained.  
Notably, the cost related to treating patients with undiagnosed diabetes is still an underexplored 
area.  A number of evaluations have been made regarding the cost of medicines but there is no 
specific approach for the methodological approach. A consensus approach on components 
included in the analysis is required to adequately allow comparison between studies.  
To strengthen the quality of future cost evaluation there should be more focus on methods of 
data collection.  Non-specific ICD-codes makes it challenging to compare studied, and hence 
often excluded due to doubt about the patient’ diagnosis. Up to October 2016 non-specific ICD-
9 and ICD-10 codes were commonly used in clinical practice.  The introduction of updated 
codes ICD-9 and ICD-10 codes which are more specific should allow more precise comparison 
between studies in future.  Another challenge is the discussion on optimal glycaemic control. 
The UKPDS (King, Peacock, & Donnelly, 1999) included young newly diagnosed patients 
who are more likely to be successful in obtaining glyceamic control compared to patients from 
the ACCORD study (Gerstein et al., 2008) who are older and less healthy.   
 
8. Limitation of methods  
This review reports on direct cost and antidiabetic medicine cost attributable to T2DM between 
2007 and 2017.  Limitations of this review included use of different methodologies and 
differences in healthcare systems across countries. We believe that it is important to address 
the complexity in the current cost-estimates used when reporting on cost of medicines as the 
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included components varies between studies. The methodological differences are for instance 
found in the inclusion criteria (table 2) and in the number of components included in the 
estimation of direct cost and cost of medicines (table 4).  Below we have raised some of the 
methodological differences between the studies:  
The setting of the study varies between the included studies. (Bahia et al., 2011) found no 
differences between secondary and tertiary levels of care, but generally there was a higher 
expenditure than in primary care.   (Borges et al., 2014) reports, that their findings may be 
biased as the study only is conducted in one diabetes care centre. Further, the direct cost may 
be underestimated as the government has kept the prices of National Health Care cost frozen 
for years. Thus, they suspect their findings does not reflect the actual annual cost of T2DM all 
over the country.   
A study conducted in the U.S shows that the cost associated with T1DM is higher than the 
prevalence of the disease and thus it is found inappropriate to combine these two groups 
when estimating the cost of diabetes (Tao, Pietropaolo, Atkinson, Schatz, & Taylor, 2010).  
An Italian study (Bruno et al., 2008) which includes patients with both T1DM and T2DM 
shows that the cost of medicines was respectively 7.7 and 2.5 times higher compared the 
control group without diabetes.   Two studies (ADA, 2013, 2018) conducted in the U.S, 
which does not differ between T1DM and T2DM, showed the cost ratio to be 3 and 2.9.  In 
contrast, two German studies (Koster, Huppertz, Hauner, & Schubert, 2014; Koster, von 
Ferber, Ihle, Schubert, & Hauner, 2006) showed that there was no difference in cost ratio was 
(cost ratio of 1.9) in both groups compared to the control group.  
The reviewed studies used different definitions for when a patient has T2DM. (Elgart et al., 
2014), identified patients between 20 and 75 years and a 2-year follow up at the hospital, and 
also had an ICD-10.  (Jacob et al., 2017), included patients over 40 years diagnosed with T2DM 
using the ICD-10 classification in the year of study (2015).   A third study (Ulrich et al., 2016) 
used data from the patient’ general practitioner. In case no valid information was available, a 
self-reported diabetes status was used. In cases where onset of disease was after 40 years 
patients were assumed to have T2DM. Patient without information about their diabetes status 
were excluded from the study. (Mata-Cases et al., 2016) reported, that they excluded 
individuals who died during the study period.  A study conducted in U.S in 2007 showed that 
mortality related cost of T2DM make more than 50 % of the direct cost, and thus the cost of 
diabetes medication may be under presented (ADA, 2008).  We believe that there is a lack 
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differentiation between T1DM and T2DM in the literature. The use of definition “T2DM” and 
using “ICD-codes” should make it easy to identify if the patient has T1DM or T2DM but in 
reality, it is not as easy as it seems. T2DM patient who are initiated on insulin-treatment may 
reclassified into T1DM after insulin initiation.   
  
Key issues  
 As prevalence increases the cost of treating complications related to T2DM will grow 
if current treatment regimens are maintained. None of the studies reviewed in this paper 
consider the cost of treating patients with undiagnosed diabetes. 
 Given the number of available medicines and treatment in achieving glyceamic control, 
it is crucial to understand the physicians’ reasons for prescribing older and newer 
antidiabetic medicines.  
 The financial burden of treating patients for T2DM is continuing to increase, and thus 
it is crucial to understand how each component contribute to these costs.  
 From the reviewed studies we were not able to find any data about if physicians’ 
consider price of medicine or the most cost-effective treatment when prescribing 
medicines to the patients. Also, the costs of patients treated with lifestyle changes and 
bariatric surgery are not being considered. 
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